Cargando…
Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon
Background. Current treatment of chronic hepatitis C with pegylated interferon and ribavirin has the ability to eliminate viral infection in about half of the patients treated. Therapeutic options, for those with remaining chronic hepatitis, will remain limited until novel antivirals become availabl...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003973/ https://www.ncbi.nlm.nih.gov/pubmed/21188197 http://dx.doi.org/10.1155/2010/537827 |
_version_ | 1782193932923305984 |
---|---|
author | Meyer, Douglas F. Tobias, Hillel Min, Albert D. Rajendra, Arathi Zic, Ivanka Brettholz, Edward Clain, David J. Klion, Franklin Bernstein, David Bodenheimer, Henry C. |
author_facet | Meyer, Douglas F. Tobias, Hillel Min, Albert D. Rajendra, Arathi Zic, Ivanka Brettholz, Edward Clain, David J. Klion, Franklin Bernstein, David Bodenheimer, Henry C. |
author_sort | Meyer, Douglas F. |
collection | PubMed |
description | Background. Current treatment of chronic hepatitis C with pegylated interferon and ribavirin has the ability to eliminate viral infection in about half of the patients treated. Therapeutic options, for those with remaining chronic hepatitis, will remain limited until novel antivirals become available in the future. Consensus interferon is currently available and has demonstrated clinical efficacy with superior invitro antiviral activity, but the maximum tolerated dose is not defined. Methods. We assessed the efficacy of daily high-dose (24 ug) consensus interferon with weight-based (1000–1200 mg daily) ribavirin in HCV genotype 1-infected non-responder patients. Results. Six adverse events were documented in five patients, and the trial was terminated with no subject achieving viral clearance. Conclusions. The occurrence of serious adverse events effectively defined the upper limit of acceptable dose, while also revealing that this dose did not offer enhanced sustained viral clearance. |
format | Text |
id | pubmed-3003973 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-30039732010-12-23 Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon Meyer, Douglas F. Tobias, Hillel Min, Albert D. Rajendra, Arathi Zic, Ivanka Brettholz, Edward Clain, David J. Klion, Franklin Bernstein, David Bodenheimer, Henry C. Hepat Res Treat Clinical Study Background. Current treatment of chronic hepatitis C with pegylated interferon and ribavirin has the ability to eliminate viral infection in about half of the patients treated. Therapeutic options, for those with remaining chronic hepatitis, will remain limited until novel antivirals become available in the future. Consensus interferon is currently available and has demonstrated clinical efficacy with superior invitro antiviral activity, but the maximum tolerated dose is not defined. Methods. We assessed the efficacy of daily high-dose (24 ug) consensus interferon with weight-based (1000–1200 mg daily) ribavirin in HCV genotype 1-infected non-responder patients. Results. Six adverse events were documented in five patients, and the trial was terminated with no subject achieving viral clearance. Conclusions. The occurrence of serious adverse events effectively defined the upper limit of acceptable dose, while also revealing that this dose did not offer enhanced sustained viral clearance. Hindawi Publishing Corporation 2010 2010-10-10 /pmc/articles/PMC3003973/ /pubmed/21188197 http://dx.doi.org/10.1155/2010/537827 Text en Copyright © 2010 Douglas F. Meyer et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Meyer, Douglas F. Tobias, Hillel Min, Albert D. Rajendra, Arathi Zic, Ivanka Brettholz, Edward Clain, David J. Klion, Franklin Bernstein, David Bodenheimer, Henry C. Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon |
title | Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon |
title_full | Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon |
title_fullStr | Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon |
title_full_unstemmed | Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon |
title_short | Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon |
title_sort | retreatment of patients nonresponsive to pegylated interferon and ribavirin with daily high-dose consensus interferon |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003973/ https://www.ncbi.nlm.nih.gov/pubmed/21188197 http://dx.doi.org/10.1155/2010/537827 |
work_keys_str_mv | AT meyerdouglasf retreatmentofpatientsnonresponsivetopegylatedinterferonandribavirinwithdailyhighdoseconsensusinterferon AT tobiashillel retreatmentofpatientsnonresponsivetopegylatedinterferonandribavirinwithdailyhighdoseconsensusinterferon AT minalbertd retreatmentofpatientsnonresponsivetopegylatedinterferonandribavirinwithdailyhighdoseconsensusinterferon AT rajendraarathi retreatmentofpatientsnonresponsivetopegylatedinterferonandribavirinwithdailyhighdoseconsensusinterferon AT zicivanka retreatmentofpatientsnonresponsivetopegylatedinterferonandribavirinwithdailyhighdoseconsensusinterferon AT brettholzedward retreatmentofpatientsnonresponsivetopegylatedinterferonandribavirinwithdailyhighdoseconsensusinterferon AT claindavidj retreatmentofpatientsnonresponsivetopegylatedinterferonandribavirinwithdailyhighdoseconsensusinterferon AT klionfranklin retreatmentofpatientsnonresponsivetopegylatedinterferonandribavirinwithdailyhighdoseconsensusinterferon AT bernsteindavid retreatmentofpatientsnonresponsivetopegylatedinterferonandribavirinwithdailyhighdoseconsensusinterferon AT bodenheimerhenryc retreatmentofpatientsnonresponsivetopegylatedinterferonandribavirinwithdailyhighdoseconsensusinterferon |